Mark Tilbury’s Golden Ratio qualifying: 7 Undervalued U.S. Stocks With Breakout Momentum

In 2019, Tilbury launched his YouTube channel with a simple promise: demystify investment fundamentals for everyday people. His first few videos, filmed on a smartphone against a makeshift backdrop, earned only a handful of views. Rather than quitting, he doubled down on consistency—posting weekly breakdowns of ETF portfolios, cryptocurrency basics, and passive income ideas. By 2021, his TikTok micro-videos—packed with quick tips on compounding returns—started going viral, catapulting him into the spotlight as a leading finance influencer.

In today’s volatile market, finding stocks that offer both value and momentum is like striking gold. Investors often chase high-growth names, but the real magic lies in identifying companies that are fundamentally strong, technically bullish, and trading at a discount. That’s exactly what we’ve uncovered using a powerful screener: U.S. stocks trading below a 20 Price-to-Earnings (P/E) ratio and showing Relative Strength Index (RSI 14) above 70—a classic signal of bullish momentum.

This combination points to companies that are not only undervalued but also gaining investor interest.

Let’s dive into seven standout stocks that meet Mark Tilbury’s golden ration criteria, grouped by market capitalization, and explore why they deserve a spot on your watchlist.

Mega-Cap Momentum: Over $200 Billion Market Cap

1. Johnson & Johnson (JNJ)

• Market Cap: $370B+
• P/E Ratio: <20
• RSI (14): >70

Johnson & Johnson is a household name in healthcare, but its stock is often overlooked by momentum traders. With a diversified portfolio spanning pharmaceuticals, medical devices, and consumer health, JNJ offers defensive stability and consistent earnings growth. Its low P/E ratio signals undervaluation, while the high RSI suggests strong recent buying pressure. For long-term investors, JNJ combines margin of safety with technical strength—a rare blend in today’s market.

2. AT&T Inc. (T)

• Market Cap: ~$210B
• P/E Ratio: ~17
• RSI (14): >70

AT&T has been a value play for years, but now it’s showing signs of momentum. With a leaner structure post-divestitures and a renewed focus on 5G and fiber, AT&T is regaining investor confidence. The ultra-low P/E ratio reflects skepticism, but the rising RSI tells a different story. This could be a turnaround moment for the telecom giant, offering both income (via dividends) and capital appreciation.

Mid-Cap Movers: $10 Billion to $200 Billion Market Cap

3. CVS Health Corp (CVS)

• Market Cap: ~$90B
• P/E Ratio: ~20
• RSI (14): >70

CVS is more than just a pharmacy chain—it’s a vertically integrated healthcare powerhouse. With its acquisition of Aetna and expansion into primary care, CVS is positioned for long-term growth. The stock’s low valuation and rising RSI suggest investors are starting to recognize its potential. CVS offers a compelling mix of growth, value, and momentum.

4. Verizon Communications (VZ)

• Market Cap: ~$189B
• P/E Ratio: ~10
• RSI (14): >70

Verizon, like AT&T, has long been a dividend darling. But now, it’s gaining traction among momentum traders. With strong cash flow, aggressive 5G rollout, and a rock-solid balance sheet, Verizon is quietly climbing. Its RSI above 70 indicates bullish sentiment, while the low P/E ratio provides a cushion against downside risk.

5. Altria Group Inc. (MO)

• Market Cap: ~$113B
• P/E Ratio: ~13
• RSI (14): >70

Altria may not be glamorous, but it’s a cash cow. Known for its high dividend yield and dominant position in tobacco, MO is a classic value stock. The recent uptick in RSI suggests renewed investor interest, possibly driven by its strategic investments in reduced-risk products. For income-focused investors, Altria offers steady returns with upside potential.

6. Leidos Holdings Inc. (LDOS)

• Market Cap: ~$23B
• P/E Ratio: ~17
• RSI (14): >70

Leidos is a leader in defense, cybersecurity, and IT services. With growing government contracts and a focus on innovation, LDOS is riding a wave of demand. Its RSI spike reflects strong momentum, while the sub-20 P/E ratio indicates it’s still attractively priced. Leidos is a tech-defense hybrid that’s flying under the radar.

7. Incyte Corp (INCY)

• Market Cap: ~$17B
• P/E Ratio: ~17
• RSI (14): >70

Incyte is a biotech firm with a promising pipeline and solid revenue from its flagship drug, Jakafi. Biotech stocks often trade at sky-high valuations, but Incyte bucks the trend. Its reasonable P/E and bullish RSI make it a rare find in the sector. For growth-oriented investors, Incyte offers innovation with a margin of safety.

In a market full of noise, these seven stocks stand out for their fundamental strength, technical momentum, and valuation appeal. Whether you’re a value investor, a swing trader, or just building a diversified portfolio, these companies offer a compelling case for further research.

Combining low P/E ratios with high RSI is a powerful strategy. The low P/E ensures you’re not overpaying, while the high RSI confirms that the market is starting to recognize the value. These stocks aren’t just cheap—they’re gaining momentum, which can lead to short-term gains and long-term compounding

Remember: momentum can fade, and valuations can shift. Always do your own due diligence and consider your risk tolerance. But if you’re looking for undervalued stocks with breakout potential, this screener might just be your new best friend